No CrossRef data available.
Article contents
Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer
Published online by Cambridge University Press: 03 December 2024
Abstract
Background:
SARS-CoV-2 asymptomatic surveillance testing (AST) is a common strategy to minimize the risk of nosocomial infection in patients and healthcare personnel. In contrast to admission screening, post-admission AST was less widely adopted.
Objective:
This study describes the diagnostic yield of post-admission serial SARS-COV-2 testing in hospitalized patients at a large cancer center with mostly double-occupancy rooms.
Design:
Retrospective cohort study design. Post-admission SARS-CoV-2 tests were examined over a 18 month study period. Positive results were reviewed to determine true hospital-onset infections using a combination criteria of screening all sample cycle threshold (Ct) values >30, results of non-concordant repeat testing, and clinical symptoms.
Results:
Post-admission serial testing of 15,048 hospitalized patients during an 18-month study period at a tertiary care cancer center detected hospital-onset infection in 1.6% (n = 245 patients). Among all hospital-onset positive SARS-CoV-2 RNA tests, 13% were clinically false positive. Most true infections were mild to moderate in severity.
Conclusions:
In summary, post-admission serial testing in a high-risk setting is a low-yield strategy with several unfavorable effects and should no longer be routinely applied.
- Type
- Original Article
- Information
- Copyright
- © Memorial Sloan Kettering Cancer Center, 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
References
Arnold, FW, Bishop, S, Oppy, L, Scott, L, Stevenson, G. Surveillance testing reveals a significant proportion of hospitalized patients with SARS-CoV-2 are asymptomatic. Am J Infect Control 2021;49:281–285. doi: 10.1016/j.ajic.2021.01.005.CrossRefGoogle ScholarPubMed
Rhee, C, Klompas, M, Pak, TR, Kohler, JR. In support of universal admission testing for SARS-CoV-2 during significant community transmission. Clin Infect Dis 2024;78:439–444. doi: 10.1093/cid/ciad424.CrossRefGoogle ScholarPubMed
Rhee, C, Baker, MA, Klompas, M. Prevention of SARS-CoV-2 and respiratory viral infections in healthcare settings: current and emerging concepts. Curr Opin Infect Dis 2022;35:353–362. doi: 10.1097/QCO.0000000000000839.CrossRefGoogle ScholarPubMed
Brust, KB, Kobayashi, T, Diekema, DJ. Asymptomatic testing of hospital admissions for SARS-CoV-2: Is it OK to stop? Clin Infect Dis 2024;78:356–360. doi: 10.1093/cid/ciad423.CrossRefGoogle Scholar
Pak, TR, Rhee, C, Wang, R, Klompas, M. Discontinuation of universal admission testing for SARS-CoV-2 and hospital-onset COVID-19 infections in England and Scotland. JAMA Intern Med 2023;183:877–880. doi: 10.1001/jamainternmed.2023.1261.CrossRefGoogle Scholar
Hatfield, KM, Baggs, J, Maillis, A, et al. Assessment of hospital-onset SARS-CoV-2 infection rates and testing practices in the US, 2020-2022. JAMA Netw Open 2023;6:e2329441. doi: 10.1001/jamanetworkopen.2023.29441.CrossRefGoogle ScholarPubMed
Babady, NE, McMillen, T, Jani, K, et al. Performance of severe acute respiratory syndrome coronavirus 2 real-time RT-PCR tests on oral rinses and saliva samples. J Mol Diagn 2021;23:3–9. doi: 10.1016/j.jmoldx.2020.10.018.CrossRefGoogle ScholarPubMed
8. McMillen, T, Jani, K, Robilotti, EV, Kamboj, M, Babady, NE. The spike gene target failure (SGTF) genomic signature is highly accurate for the identification of Alpha and Omicron SARS-CoV-2 variants. Sci Rep 2022;12:18968. doi: 10.1038/s41598-022-21564-y.CrossRefGoogle ScholarPubMed
Prabhu, RM, Firestone, MJ, Bergman, KL, et al. Use of serial testing to interrupt a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) outbreak on a hospital medical floor-Minnesota, October-December 2020. Infect Control Hosp Epidemiol 2023;44:427–432. doi: 10.1017/ice.2022.40.CrossRefGoogle ScholarPubMed
Uno, S, Goto, R, Honda, K, et al. Cost-effectiveness of universal asymptomatic preoperative SARS-CoV-2 polymerase chain reaction screening: A cost-utility analysis. Clin Infect Dis 2024; 78:57–64. doi: 10.1093/cid/ciad463.CrossRefGoogle ScholarPubMed